AZ, Scorpion strike deal on elusive transcription factor targets in cancerAstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in Share XAZ, Scorpion strike deal on elusive transcription factor targets in cancerhttps://pharmaphorum.com/news/az-scorpion-strike-deal-on-elusive-transcription-factor-targets-in-cancer/
Sanofi places $75m bet with ABL on popular Parkinson’s drug targetSanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a Share XSanofi places $75m bet with ABL on popular Parkinson’s drug targethttps://pharmaphorum.com/news/sanofi-places-75m-bet-with-abl-on-popular-parkinsons-drug-target/
Bayer trumpets $1bn CRISPR deal with Mammoth BioBayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed Share XBayer trumpets $1bn CRISPR deal with Mammoth Biohttps://pharmaphorum.com/news/bayer-trumpets-crispr-deal-mammoth-bio/
After trial win, Novartis nabs COVID drug from Molecular PartnersThere are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around Share XAfter trial win, Novartis nabs COVID drug from Molecular Partnershttps://pharmaphorum.com/news/after-trial-win-novartis-nabs-covid-drug-from-molecular-partners/
Another big AI deal as Sanofi taps Exscientia for 15 new drugsIf the last couple of days is an indication, 2022 is already shaping up to be the year Share XAnother big AI deal as Sanofi taps Exscientia for 15 new drugshttps://pharmaphorum.com/news/another-big-ai-deal-as-sanofi-taps-exscientia-for-15-new-drugs/
Roivant joins RNA splicing push with Eisai dealRoivant is the latest pharma group to take a position in the emerging field of therapies targeted at Share XRoivant joins RNA splicing push with Eisai dealhttps://pharmaphorum.com/news/roivant-joins-rna-splicing-push-with-eisai-deal/
Otsuka dips its toe in psychedelic waters, backing Mindset PharmaDespite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary Share XOtsuka dips its toe in psychedelic waters, backing Mindset Pharmahttps://pharmaphorum.com/news/otsuka-dips-its-toe-in-psychedelic-waters-backing-mindset-pharma/
Look out GSK, Pfizer and BioNTech are coming for ShingrixGlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. Share XLook out GSK, Pfizer and BioNTech are coming for Shingrixhttps://pharmaphorum.com/news/look-out-gsk-pfizer-and-biontech-are-coming-for-shingrix/
Ipsen places €480m bet on Genfit’s liver drug elafibranorGenfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis Share XIpsen places €480m bet on Genfit’s liver drug elafibranorhttps://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/
